Presentation of clinical validation of Histotype Px® Colorectal in U.S. colon cancer patients at the 2024 ASCO Annual Meeting
OSLO – May 29, 2024 – DoMore Diagnostics, a leader in AI and deep-learning for precision medicine for cancer, is pleased to announce that an abstract with the first clinical validation pilot of Histotype Px® Colorectal (Histotype Px) on a U.S. colon cancer cohort has been accepted at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, Chicago, IL). Building on previously published validations in European colorectal cancer patient cohorts, the study was conducted by The Ohio State University Comprehensive Cancer Center (OSUCCC) and supports the clinical applicability of Histotype Px in a U.S. patient cohort.
The study, involving 159 patients (mean age 63 years) with stage II and stage III colon cancer diagnosed and treated at OSUCCC between 2016 and 2020, found that Histotype Px effectively risk stratifies patients into low, intermediate, and high-risk groups and showed it was a significant predictor of patient outcomes. Specifically, for high vs. low-risk patients, the digital biomarker predicted cancer-specific survival (HR=7.80, p<0.001) and time-to-recurrence (HR=7.59, p<0.001). These encouraging results will be followed up with larger data sets to further document Histotype Px as a clinical decision tool.
Principal Investigator Dr. Eric D. Miller, MD, PhD, OSUCCC said: “According to current US guidelines most high risk stage II and stage III colon cancer patients should receive ACT, however most patients have a low risk of recurrence and do not benefit from this treatment. There is a medical need for better biomarkers to guide clinical decision making. The pilot validation data we will present at the 2024 ASCO annual meeting confirms the potential clinical utility of Histotype Px in this setting and future studies will aim to further validate these results in a larger patient cohort.”
Torbjørn Furuseth, MD, Co-Founder and CEO at DoMore Diagnostics, commented, "The acceptance of the U.S. validation data at the ASCO Annual Meeting is a further testament to the significant impact Histotype Px can have on colorectal cancer as a new standard of care clinical decision tool and an important step towards clinical implementation. We are excited about the potential of Histotype Px to revolutionize patient care by providing oncologists with critical insights that guide more effective and personalized treatment strategies."
Live poster session: Hall A, Abstract 3622, Poster Board 285 @ 1 June 2024, 1:30 PM-4:30 PM CDT
Citation: J Clin Oncol 42, 2024 (suppl 16; abstr 3622)
Published Abstract can be found here.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefitting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
The Lancet publication.
The Lancet Oncology publication.
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com